[{"address1": "80 Guest Street", "address2": "Suite 601", "city": "Boston", "state": "MA", "zip": "02135", "country": "United States", "phone": "617 500 8099", "website": "https://www.compasstherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in the development of antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidates include tovecimig, a bispecific antibody that blocks Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization; CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; and CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies. It also develops CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A; and VEGF-IO Bispecific / Multiple, a bispecific antibody engages the angiogenesis pathway and anti-tumor immune that targets, including immune checkpoints, as well as analyzes VEGF combinations with other immune response-related proteins. Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 35, "companyOfficers": [{"maxAge": 1, "name": "Dr. Thomas J. Schuetz M.D., Ph.D.", "age": 63, "title": "CEO & Vice Chairman", "yearBorn": 1961, "fiscalYear": 2024, "totalPay": 994800, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Barry  Shin J.D., M.B.A.", "age": 52, "title": "Chief Financial Officer", "yearBorn": 1972, "fiscalYear": 2024, "totalPay": 406256, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jonathan E. Anderman J.D.", "title": "Senior VP, General Counsel & Corporate Secretary", "fiscalYear": 2024, "totalPay": 541620, "exercisedValue": 0, "unexercisedValue": 6250}, {"maxAge": 1, "name": "Ms. Vered  Bisker-Leib MBA, Ph.D.", "age": 53, "title": "Advisor", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 1531657, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Anna  Gifford", "title": "Communications Manager", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Minori  Rosales M.D., Ph.D.", "age": 61, "title": "Senior VP & Head of Clinical Development", "yearBorn": 1963, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Karin  Herrera B.A.", "title": "Senior VP & Head of Clinical Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. James  Kranz Ph.D.", "title": "VP and Head of Chemistry Manufacturing & Controls", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 8, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1746057600, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.76, "open": 1.68, "dayLow": 1.67, "dayHigh": 1.81, "regularMarketPreviousClose": 1.76, "regularMarketOpen": 1.68, "regularMarketDayLow": 1.67, "regularMarketDayHigh": 1.81, "payoutRatio": 0.0, "beta": 1.189, "forwardPE": -3.5, "volume": 312380, "regularMarketVolume": 312380, "averageVolume": 1498713, "averageVolume10days": 820950, "averageDailyVolume10Day": 820950, "bid": 1.73, "ask": 1.81, "bidSize": 1, "askSize": 2, "marketCap": 246833360, "fiftyTwoWeekLow": 0.765, "fiftyTwoWeekHigh": 4.08, "priceToSalesTrailing12Months": 290.39218, "fiftyDayAverage": 2.1077, "twoHundredDayAverage": 1.89496, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 123289200, "profitMargins": 0.0, "floatShares": 91483552, "sharesOutstanding": 138282000, "sharesShort": 8169591, "sharesShortPriorMonth": 4607296, "sharesShortPreviousMonthDate": 1741910400, "dateShortInterest": 1744675200, "sharesPercentSharesOut": 0.0591, "heldPercentInsiders": 0.19788, "heldPercentInstitutions": 0.66365, "shortRatio": 3.14, "shortPercentOfFloat": 0.111999996, "impliedSharesOutstanding": 138282000, "bookValue": 0.909, "priceToBook": 1.9636964, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -49375000, "trailingEps": -0.36, "forwardEps": -0.51, "enterpriseToRevenue": 145.046, "enterpriseToEbitda": -2.2, "52WeekChange": 0.106918216, "SandP52WeekChange": 0.08001411, "quoteType": "EQUITY", "currentPrice": 1.785, "targetHighPrice": 32.0, "targetLowPrice": 6.0, "targetMeanPrice": 13.1, "targetMedianPrice": 10.5, "recommendationMean": 1.3, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 10, "totalCash": 126722000, "totalCashPerShare": 0.916, "ebitda": -56036000, "totalDebt": 6634000, "quickRatio": 14.28, "currentRatio": 14.96, "totalRevenue": 850000, "debtToEquity": 5.297, "revenuePerShare": 0.006, "returnOnAssets": -0.23809999, "returnOnEquity": -0.3607, "grossProfits": 850000, "freeCashflow": -27798624, "operatingCashflow": -44855000, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -66.61765, "financialCurrency": "USD", "symbol": "CMPX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketChangePercent": 1.4204532, "regularMarketPrice": 1.785, "regularMarketTime": 1746724320, "exchange": "NCM", "messageBoardId": "finmb_266166780", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "shortName": "Compass Therapeutics, Inc.", "longName": "Compass Therapeutics, Inc.", "corporateActions": [], "marketState": "REGULAR", "regularMarketChange": 0.024999976, "regularMarketDayRange": "1.67 - 1.81", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 1498713, "fiftyTwoWeekLowChange": 1.02, "fiftyTwoWeekLowChangePercent": 1.3333334, "fiftyTwoWeekRange": "0.765 - 4.08", "fiftyTwoWeekHighChange": -2.295, "fiftyTwoWeekHighChangePercent": -0.5625, "fiftyTwoWeekChangePercent": 10.691822, "earningsTimestamp": 1746707400, "earningsTimestampStart": 1746707400, "earningsTimestampEnd": 1746707400, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -0.36, "epsForward": -0.51, "epsCurrentYear": -0.46667, "priceEpsCurrentYear": -3.8249726, "fiftyDayAverageChange": -0.32270014, "fiftyDayAverageChangePercent": -0.15310533, "twoHundredDayAverageChange": -0.10996008, "twoHundredDayAverageChangePercent": -0.05802765, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-11-02", "averageAnalystRating": "1.3 - Strong Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1617629400000, "displayName": "Compass Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-05-08"}]